Nasdaq · CIK 0001800315
DMRA Galecto, Inc.
Insider trading from SEC Form 4. Last filing 14 d ago. Close $21.08 on Oct 9, 2026, +326% from the 52-week low and -38% from the high.
Last 90 days
Net insider value
+$253k
more bought than sold
Buys
1
$253k by 1 insider
Sells
0
$0 by 0 insiders
Insiders on file
18
with a Form 4 at this company
Price and insider trades, last year
DMRAOct 9, 2026 · close 21.08
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Galecto, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | Jennifer Jarrett Director, President and CEO buy | $253k 12,500 shares | +3% | - | |
| 27Weak | Lori Firmani Chief Financial Officer sell | $2,890 135 shares | -13% | +883% from low-36% from high | |
| 20Weak | Garrett Winslow General Counsel sell | $5,452 255 shares | -12% | +883% from low-36% from high | |
| 30Weak | Hans T. Schambye Chief Executive Officer sell | $15k 700 shares | -13% | +883% from low-36% from high | |
| 27Weak | Lori Firmani Interim CFO sell | $498 147 shares | -18% | +59% from low-75% from high | |
| 20Weak | Garrett Winslow General Counsel sell | $881 260 shares | -15% | +59% from low-75% from high | |
| 30Weak | Hans T. Schambye Chief Executive Officer sell | $2,484 735 shares | -15% | +59% from low-75% from high | |
| 32Weak | Lori Firmani Interim CFO sell | $1,469 261 shares | -36% | - | |
| 35Weak | Hans T. Schambye Chief Executive Officer sell | $7,510 1,341 shares | -28% | - | |
| 25Weak | Garrett Winslow General Counsel sell | $2,638 471 shares | -32% | - |
Transactions
The last 60 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 25, 2026 | Jennifer Jarrett Director, President and CEO | POpen-market purchase Ordinary Shares | +12,500 | $20.23 | $253k | 512,500 | 14 d ago |
| Mar 23, 2026 | Julianne Bruno director | AGrant or award Stock Option (right to buy)derivative | +37,313 | $0.00 | $0 | 37,313 | Mar 25, 2026 |
| Mar 23, 2026 | Garrett Winslow General Counsel | AGrant or award Stock Option (right to buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Mar 25, 2026 |
| Mar 23, 2026 | Cameron Turtle director | AGrant or award Stock Option (right to buy)derivative | +37,313 | $0.00 | $0 | 37,313 | Mar 25, 2026 |
| Mar 23, 2026 | Fairmount Funds Management LLC director, owner | AGrant or award Stock Option (right to buy)derivativeindirect: By: Peter Harwin | +37,313 | $0.00 | $0 | 37,313 | Mar 25, 2026 |
| Mar 23, 2026 | Christopher W. Cain director | AGrant or award Stock Option (right to buy)derivative | +37,313 | $0.00 | $0 | 37,313 | Mar 25, 2026 |
| Mar 23, 2026 | Michael Landsittel director | AGrant or award Stock Option (right to buy)derivative | +37,313 | $0.00 | $0 | 37,313 | Mar 25, 2026 |
| Feb 9, 2026 | Julianne Bruno director | MOption exercise Common Stock | +129,000 | $0.00 | $0 | 137,032 | Feb 12, 2026 |
| Feb 9, 2026 | Fairmount Funds Management LLC director, owner | MOption exercise Common Stockindirect: By Fairmount Healthcare Fund II L.P. | +5,809,000 | $0.00 | $0 | 5,809,000 | Feb 12, 2026 |
| Feb 9, 2026 | Julianne Bruno director | MOption exercise Series C Preferred Stockderivative | -129 | $0.00 | $0 | 0 | Feb 12, 2026 |
| Feb 9, 2026 | Fairmount Funds Management LLC director, owner | MOption exercise Common Stockindirect: By Fairmount Healthcare Co-Invest V L.P. | +2,904,000 | $0.00 | $0 | 2,904,000 | Feb 12, 2026 |
| Feb 9, 2026 | Fairmount Funds Management LLC director, owner | MOption exercise Series C Preferred Stockderivativeindirect: By Fairmount Healthcare Fund II L.P. | -5,809 | $0.00 | $0 | 1,148 | Feb 12, 2026 |
| Feb 9, 2026 | Fairmount Funds Management LLC director, owner | MOption exercise Series C Preferred Stockderivativeindirect: By Fairmount Healthcare Co-Invest V L.P. | -2,904 | $0.00 | $0 | 574 | Feb 12, 2026 |
| Jan 5, 2026 | Sherwin Sattarzadeh Chief Operating Officer | AGrant or award Common Stock | +190,376 | $0.00 | $0 | 190,376 | Jan 26, 2026 |
| Jan 5, 2026 | Sherwin Sattarzadeh Chief Operating Officer | AGrant or award Stock Option (right to buy)derivative | +444,209 | $0.00 | $0 | 444,209 | Jan 26, 2026 |
| Jan 5, 2026 | L. Becker Hewes Chief Medical Officer | AGrant or award Common Stock | +264,629 | $0.00 | $0 | 264,629 | Jan 7, 2026 |
| Jan 5, 2026 | L. Becker Hewes Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +528,603 | $0.00 | $0 | 528,603 | Jan 7, 2026 |
| Jan 2, 2026 | Lori Firmani Chief Financial Officer | MOption exercise Common Stock | +374 | - | - | 1,066 | Jan 6, 2026 |
| Jan 2, 2026 | Hans T. Schambye Chief Executive Officer | MOption exercise Common Stock | +1,360 | - | - | 5,382 | Jan 6, 2026 |
| Jan 2, 2026 | Garrett Winslow General Counsel | MOption exercise Common Stock | +680 | - | - | 2,109 | Jan 6, 2026 |
| Jan 2, 2026 | Garrett Winslow General Counsel | SOpen-market sale Common Stock | -255 | $21.38 | $5,452 | 1,854 | Jan 6, 2026 |
| Jan 2, 2026 | Lori Firmani Chief Financial Officer | SOpen-market sale Common Stock | -135 | $21.41 | $2,890 | 931 | Jan 6, 2026 |
| Jan 2, 2026 | Hans T. Schambye Chief Executive Officer | SOpen-market sale Common Stock | -700 | $21.38 | $15k | 4,682 | Jan 6, 2026 |
| Jan 2, 2026 | Lori Firmani Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -374 | $0.00 | $0 | 726 | Jan 6, 2026 |
| Jan 2, 2026 | Garrett Winslow General Counsel | MOption exercise Restricted Stock Unitsderivative | -680 | $0.00 | $0 | 1,320 | Jan 6, 2026 |
| Jan 2, 2026 | Hans T. Schambye Chief Executive Officer | MOption exercise Restricted Stock Unitsderivative | -1,360 | $0.00 | $0 | 2,640 | Jan 6, 2026 |
| Jul 3, 2025 | Lori Firmani Interim CFO | MOption exercise Common Stock | +374 | - | - | 839 | Jul 8, 2025 |
| Jul 3, 2025 | Hans T. Schambye Chief Executive Officer | MOption exercise Common Stock | +1,360 | - | - | 4,757 | Jul 8, 2025 |
| Jul 3, 2025 | Garrett Winslow General Counsel | MOption exercise Common Stock | +680 | - | - | 1,689 | Jul 8, 2025 |
| Jul 3, 2025 | Hans T. Schambye Chief Executive Officer | SOpen-market sale Common Stock | -735 | $3.38 | $2,484 | 4,022 | Jul 8, 2025 |
| Jul 3, 2025 | Garrett Winslow General Counsel | SOpen-market sale Common Stock | -260 | $3.39 | $881 | 1,429 | Jul 8, 2025 |
| Jul 3, 2025 | Lori Firmani Interim CFO | SOpen-market sale Common Stock | -147 | $3.39 | $498 | 692 | Jul 8, 2025 |
| Jul 3, 2025 | Lori Firmani Interim CFO | MOption exercise Restricted Stock Unitsderivative | -374 | $0.00 | $0 | 1,100 | Jul 8, 2025 |
| Jul 3, 2025 | Hans T. Schambye Chief Executive Officer | MOption exercise Restricted Stock Unitsderivative | -1,360 | $0.00 | $0 | 4,000 | Jul 8, 2025 |
| Jul 3, 2025 | Garrett Winslow General Counsel | MOption exercise Restricted Stock Unitsderivative | -680 | $0.00 | $0 | 2,000 | Jul 8, 2025 |
| Jun 18, 2025 | Jayson Donald Alexander Dallas director | AGrant or award Stock Option (right to buy)derivative | +720 | $0.00 | $0 | 720 | Jun 20, 2025 |
| Jun 18, 2025 | Carl Goldfischer director | AGrant or award Stock Option (right to buy)derivative | +1,440 | $0.00 | $0 | 1,440 | Jun 20, 2025 |
| Jun 18, 2025 | Amy B Wechsler director | AGrant or award Stock Option (right to buy)derivative | +720 | $0.00 | $0 | 720 | Jun 20, 2025 |
| Jun 18, 2025 | Anne Prener director | AGrant or award Stock Option (right to buy)derivative | +720 | $0.00 | $0 | 720 | Jun 20, 2025 |
| Jun 18, 2025 | David Shapiro director | AGrant or award Stock Option (right to buy)derivative | +720 | $0.00 | $0 | 720 | Jun 20, 2025 |
| Jun 18, 2025 | Amit Munshi director | AGrant or award Stock Option (right to buy)derivative | +720 | $0.00 | $0 | 720 | Jun 20, 2025 |
| Jan 3, 2025 | Hans T. Schambye Chief Executive Officer | MOption exercise Common Stock | +2,640 | - | - | 4,738 | Jan 7, 2025 |
| Jan 3, 2025 | Garrett Winslow General Counsel | MOption exercise Common Stock | +1,320 | - | - | 1,480 | Jan 7, 2025 |
| Jan 3, 2025 | Matthew Kronmiller EVP Strategy and CBO | AGrant or award Stock Option (right to buy)derivative | +6,000 | $0.00 | $0 | 6,000 | Jan 7, 2025 |
| Jan 3, 2025 | Lori Firmani Interim CFO | MOption exercise Common Stock | +726 | - | - | 726 | Jan 7, 2025 |
| Jan 3, 2025 | Hans T. Schambye Chief Executive Officer | SOpen-market sale Common Stock | -1,341 | $5.60 | $7,510 | 3,397 | Jan 7, 2025 |
| Jan 3, 2025 | Lori Firmani Interim CFO | SOpen-market sale Common Stock | -261 | $5.63 | $1,469 | 465 | Jan 7, 2025 |
| Jan 3, 2025 | Garrett Winslow General Counsel | SOpen-market sale Common Stock | -471 | $5.60 | $2,638 | 1,009 | Jan 7, 2025 |
| Jan 3, 2025 | Lori Firmani Interim CFO | MOption exercise Restricted Stock Unitsderivative | -726 | $0.00 | $0 | 1,474 | Jan 7, 2025 |
| Jan 3, 2025 | Hans T. Schambye Chief Executive Officer | MOption exercise Restricted Stock Unitsderivative | -2,640 | $0.00 | $0 | 5,360 | Jan 7, 2025 |
| Jan 3, 2025 | Garrett Winslow General Counsel | MOption exercise Restricted Stock Unitsderivative | -1,320 | $0.00 | $0 | 2,680 | Jan 7, 2025 |
| Jan 3, 2025 | Lori Firmani Interim CFO | AGrant or award Stock Option (right to buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jan 7, 2025 |
| Jan 3, 2025 | Hans T. Schambye Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +16,400 | $0.00 | $0 | 16,400 | Jan 7, 2025 |
| Jan 3, 2025 | Garrett Winslow General Counsel | AGrant or award Stock Option (right to buy)derivative | +6,000 | $0.00 | $0 | 6,000 | Jan 7, 2025 |
| Oct 11, 2024 | Amy B Wechsler director | AGrant or award Stock Option (right to buy)derivative | +720 | $0.00 | $0 | 720 | Oct 15, 2024 |
| Oct 11, 2024 | Amy B Wechsler director | AGrant or award Stock Option (right to buy)derivative | +480 | $0.00 | $0 | 480 | Oct 15, 2024 |
| Oct 9, 2024 | Lori Firmani Interim CFO | AGrant or award Stock Option (right to buy)derivative | +13,000 | $0.00 | $0 | 13,000 | Oct 11, 2024 |
| Oct 9, 2024 | Hans T. Schambye Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +44,100 | $0.00 | $0 | 44,100 | Oct 11, 2024 |
| Oct 9, 2024 | Matthew Kronmiller EVP Strategy and CBO | AGrant or award Stock Option (right to buy)derivative | +8,600 | $0.00 | $0 | 8,600 | Oct 11, 2024 |
| Oct 9, 2024 | Garrett Winslow General Counsel | AGrant or award Stock Option (right to buy)derivative | +15,600 | $0.00 | $0 | 15,600 | Oct 11, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Julianne Brunocoo, officer, director
- Christopher W. Caindirector
- Jayson Donald Alexander Dallasdirector
- Fairmount Funds Management LLCdirector, owner
- Lori FirmaniChief Financial Officer
- Carl Goldfischerdirector
- L. Becker HewesChief Medical Officer
- Jennifer JarrettDirector, President and CEO
- Matthew KronmillerEVP Strategy and CBO
- Michael Landsittelcfo, officer, director
- Amit Munshidirector
- Anne Prenerdirector
- Sherwin SattarzadehChief Operating Officer
- Hans T. SchambyeChief Executive Officer
- David Shapirodirector
- Cameron Turtleceo, officer, director
- Amy B Wechslerdirector
- Garrett WinslowGeneral Counsel
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.